Open Payments

Karmanos Cancer Hospital

Type
Teaching hospital
Where
Detroit, MI
Medicare CCN
230297
Received
$5,691,545 in 1,135 records, 2022 ($102,276 general, $5,589,268 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment13$102,276
2022Research payment1,122$5,589,268

By company

CompanyRecordsAmountYears
Regeneron Pharmaceuticals, Inc.166$960,4202022
Merck Sharp & Dohme LLC61$815,5962022
Genentech, Inc.130$702,0682022
Alkermes, Inc.66$551,0972022
Janssen Research & Development, LLC173$397,2362022
Celgene Corporation12$283,0302022
EMD Serono, Inc.24$249,2952022
AstraZeneca Pharmaceuticals LP12$133,8362022
E.R. Squibb & Sons, L.L.C.10$132,9562022
National Marrow Donor Program15$132,0072022
SEAGEN INC.57$126,2592022
Gilead Sciences, Inc.31$123,5922022
Daiichi Sankyo Inc.25$99,2802022
CSL Behring9$92,1042022
Takeda Pharmaceuticals U.S.A., Inc.48$77,2462022
Boehringer Ingelheim Pharmaceuticals, Inc.1$73,4492022
Novartis Pharmaceuticals Corporation3$68,3082022
Kite Pharma, Inc.13$60,0632022
BeiGene, Ltd.19$56,3772022
Bayer Healthcare Pharmaceuticals Inc.24$55,5602022
Incyte Corporation52$52,4982022
Alexion Pharmaceuticals, Inc.4$43,9402022
Eli Lilly and Company3$38,4742022
SANOFI US SERVICES INC.21$36,3672022
Clovis Oncology, Inc.10$35,9042022
Exelixis Inc.28$34,5482022
Pharmacyclics LLC, an AbbVie Company31$31,6802022
ADC THERAPEUTICS AMERICA, INC.1$28,9682022
Aveo Pharmaceuticals, Inc.7$27,8002022
ABBVIE INC.17$27,4942022
AstraZeneca UK Limited2$20,2452022
Novocure Inc.18$19,4742022
TRILLIUM THERAPEUTICS USA, LLC5$18,9212022
Tactile Systems Technology Inc1$18,0402022
PFIZER INC.16$12,6652022
Boehringer Ingelheim International GmbH1$12,4302022
MorphoSys, US Inc.1$10,0002022
Karyopharm Therapeutics Inc.1$8,0002022
Blue Earth Diagnostics5$6,9382022
Acerta Pharma LLC1$5,6602022
Stemline Therapeutics Inc.3$4,9362022
Adaptive Biotechnologies Corporation1$3,5002022
Astellas Pharma Global Development3$2,2752022
Amgen Inc.1$5002022
Servier BioInnovation1$2002022
Radius Health, Inc.1$2002022
Siemens Medical Solutions USA, Inc.1$922022

By nature of payment

NatureRecordsAmount
Research payment1,122$5,589,268
Compensation for services other than consulting, including serving as faculty or as a speaker at a v5$65,684
Space rental or facility fees (teaching hospital only)7$36,500
Debt forgiveness1$92

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Merck Sharp & Dohme LLC$92,341Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792022
2022-12-31Merck Sharp & Dohme LLC$63,372Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab MK-7684 with Pembrolizumab M2022
2022-12-31Merck Sharp & Dohme LLC$56,944Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r2022
2022-12-31Merck Sharp & Dohme LLC$45,677Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini2022
2022-12-31Merck Sharp & Dohme LLC$28,472Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2022
2022-12-31Merck Sharp & Dohme LLC$27,336Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly2022
2022-12-31Merck Sharp & Dohme LLC$21,354Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2022
2022-12-31Merck Sharp & Dohme LLC$21,234Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2022
2022-12-31Merck Sharp & Dohme LLC$16,574Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad2022
2022-12-31Merck Sharp & Dohme LLC$15,082Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r2022
2022-12-31Merck Sharp & Dohme LLC$14,788Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini2022
2022-12-31Merck Sharp & Dohme LLC$13,032Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2022
2022-12-31Merck Sharp & Dohme LLC$12,681Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2022
2022-12-31Merck Sharp & Dohme LLC$11,642Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792022
2022-12-31Merck Sharp & Dohme LLC$9,562Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2022
2022-12-31Merck Sharp & Dohme LLC$8,776Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYAn Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly2022
2022-12-31Merck Sharp & Dohme LLC$7,603Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with2022
2022-12-31Merck Sharp & Dohme LLC$7,496Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2022
2022-12-31Merck Sharp & Dohme LLC$7,172Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini2022
2022-12-31Merck Sharp & Dohme LLC$6,825Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad2022
2022-12-31Merck Sharp & Dohme LLC$6,709Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r2022
2022-12-31Merck Sharp & Dohme LLC$6,655Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi2022
2022-12-31Merck Sharp & Dohme LLC$6,139Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R2022
2022-12-31Merck Sharp & Dohme LLC$5,860Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv2022
2022-12-31Merck Sharp & Dohme LLC$5,274Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A2022
2022-12-31Merck Sharp & Dohme LLC$4,820Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly2022
2022-12-31Merck Sharp & Dohme LLC$4,794Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad2022
2022-12-31Merck Sharp & Dohme LLC$4,387Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r2022
2022-12-31Merck Sharp & Dohme LLC$4,360Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792022
2022-12-31Merck Sharp & Dohme LLC$4,246Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi2022
2022-12-31Merck Sharp & Dohme LLC$4,125Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2022
2022-12-31Merck Sharp & Dohme LLC$3,555Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2022
2022-12-31Merck Sharp & Dohme LLC$2,466Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with2022
2022-12-31Merck Sharp & Dohme LLC$2,431Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2022
2022-12-31Merck Sharp & Dohme LLC$1,892Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2022
2022-12-31Merck Sharp & Dohme LLC$1,840Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly2022
2022-12-31Merck Sharp & Dohme LLC$1,545Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R2022
2022-12-31Merck Sharp & Dohme LLC$1,290Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-12022
2022-12-31Merck Sharp & Dohme LLC$1,023Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2022
2022-12-31AstraZeneca Pharmaceuticals LP$1,010Research paymentIn-kind items and servicesA Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) i2022
2022-12-31AstraZeneca Pharmaceuticals LP$517Research paymentIn-kind items and servicesIMFINZI Biological, OncologyA Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co2022
2022-12-31Merck Sharp & Dohme LLC$364Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-12022
2022-12-31Merck Sharp & Dohme LLC$227Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini2022
2022-12-31Merck Sharp & Dohme LLC$149Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2022
2022-12-31Merck Sharp & Dohme LLC$136Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2022
2022-12-31Merck Sharp & Dohme LLC$90Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with 2022
2022-12-31Merck Sharp & Dohme LLC$22Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refracto2022
2022-12-31Merck Sharp & Dohme LLC$19Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase Ib Trial of Pembrolizumab MK-3475 in Combination with Dinaciclib MK-7965 in Subjects with Hematologic Malignancies2022
2022-12-29TRILLIUM THERAPEUTICS USA, LLC$8,266Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2022
2022-12-29Genentech, Inc.$2,500Research paymentCash or cash equivalent DrugLIGHT CHAIN AMYLOIDOSIS REAL WORLD EVIDENCE RWE CONSORTIUM LARC2022
2022-12-28Daiichi Sankyo Inc.$2,500Research paymentCash or cash equivalentDS1062-A-U3012022
2022-12-28BeiGene, Ltd.$2,000Research paymentCash or cash equivalentA Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Ho2022
2022-12-28Daiichi Sankyo Inc.$500Research paymentCash or cash equivalentENHERTU Drug, ONCOLOGYDS-8201-A-U2042022
2022-12-28Regeneron Pharmaceuticals, Inc.$400Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2022
2022-12-27Genentech, Inc.$1,000Research paymentCash or cash equivalentLUNSUMIO Biological, BioOncologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22022
2022-12-26Janssen Research & Development, LLC$858Research paymentCash or cash equivalentA Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub2022
2022-12-26Janssen Research & Development, LLC$858Research paymentCash or cash equivalentA Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit2022
2022-12-22Alkermes, Inc.$38,025Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2022
2022-12-22Aveo Pharmaceuticals, Inc.$14,000Research paymentCash or cash equivalentFOTIVDA Drug, OncologyTiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo2022
2022-12-22Aveo Pharmaceuticals, Inc.$4,760Research paymentCash or cash equivalentFOTIVDA Drug, OncologyTiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo2022
2022-12-22Aveo Pharmaceuticals, Inc.$2,040Research paymentCash or cash equivalentFOTIVDA Drug, OncologyTiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo2022
2022-12-22Aveo Pharmaceuticals, Inc.$2,000Research paymentCash or cash equivalentFOTIVDA Drug, OncologyTiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo2022
2022-12-22Aveo Pharmaceuticals, Inc.$2,000Research paymentCash or cash equivalentFOTIVDA Drug, OncologyTiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo2022
2022-12-22Aveo Pharmaceuticals, Inc.$2,000Research paymentCash or cash equivalentFOTIVDA Drug, OncologyTiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo2022
2022-12-22SANOFI US SERVICES INC.$1,500Research paymentCash or cash equivalentREZUROCK Drug, OncologyA Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Ver2022
2022-12-22SANOFI US SERVICES INC.$1,500Research paymentCash or cash equivalentREZUROCK Drug, OncologyA Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Ver2022
2022-12-22SANOFI US SERVICES INC.$1,320Research paymentCash or cash equivalentREZUROCK Drug, OncologyA Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Ver2022
2022-12-22Aveo Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentFOTIVDA Drug, OncologyTiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo2022
2022-12-22Regeneron Pharmaceuticals, Inc.$645Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2022
2022-12-22Bayer Healthcare Pharmaceuticals Inc.$418Research paymentCash or cash equivalentXofigo Drug, OncologyLong Term follow up with Xofigo2022
2022-12-22SEAGEN INC.$300Research paymentCash or cash equivalentA Phase 1 Study of SEA-CD70 in Myeloid Malignancies2022
2022-12-22SANOFI US SERVICES INC.$158Research paymentCash or cash equivalentREZUROCK Drug, OncologyA Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Ver2022
2022-12-21Genentech, Inc.$8,533Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyA PHASE II STUDY EVALUATING SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB2022
2022-12-21Celgene Corporation$1,890Research paymentCash or cash equivalent(CC-92480-MM-002) Phase IIA - DMCP Managed Basket Trial2022
2022-12-19Merck Sharp & Dohme LLC$18,498Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini2022
2022-12-19Janssen Research & Development, LLC$16,120Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas2022
2022-12-19Genentech, Inc.$8,140Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2022
2022-12-19Janssen Research & Development, LLC$4,939Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas2022
2022-12-19Janssen Research & Development, LLC$2,386Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-12-19Janssen Research & Development, LLC$2,000Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-12-19Janssen Research & Development, LLC$260Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-12-19Janssen Research & Development, LLC$68Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-12-16Janssen Research & Development, LLC$2,926Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-12-16Janssen Research & Development, LLC$2,774Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-12-16Janssen Research & Development, LLC$2,697Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-12-16Janssen Research & Development, LLC$200Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-12-16Janssen Research & Development, LLC$200Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-12-16Janssen Research & Development, LLC$200Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-12-16Janssen Research & Development, LLC$200Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-12-16Janssen Research & Development, LLC$72Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-12-15Novocure Inc.$1,500Research paymentCash or cash equivalentEF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and2022
2022-12-15Novocure Inc.$1,000Research paymentCash or cash equivalentEF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and2022
2022-12-15EMD Serono, Inc.$500Research paymentCash or cash equivalentA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera2022
2022-12-15EMD Serono, Inc.$476Research paymentCash or cash equivalentA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera2022
2022-12-14SEAGEN INC.$1,500Research paymentCash or cash equivalentTIVDAK Biological, OncologyOpen Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o2022
2022-12-14Genentech, Inc.$1,428Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2022
2022-12-13Genentech, Inc.$8,886Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22022
2022-12-13Genentech, Inc.$8,539Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22022
2022-12-13Genentech, Inc.$6,121Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22022
2022-12-13Genentech, Inc.$1,320Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22022
2022-12-13Genentech, Inc.$1,320Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22022
2022-12-13Genentech, Inc.$1,000Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22022
2022-12-13Janssen Research & Development, LLC$573Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas2022
2022-12-13Janssen Research & Development, LLC$530Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas2022
2022-12-12Genentech, Inc.$30,672Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22022
2022-12-12Janssen Research & Development, LLC$6,200Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-12-09National Marrow Donor Program$13,500Research paymentCash or cash equivalentA Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplant2022
2022-12-09Takeda Pharmaceuticals U.S.A., Inc.$200Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2022
2022-12-08Boehringer Ingelheim Pharmaceuticals, Inc.$73,449Research paymentCash or cash equivalentOFEV Drug, RESPIRATORYmalignant pleural mesothelioma US2022
2022-12-08EMD Serono, Inc.$5,465Research paymentCash or cash equivalentA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera2022
2022-12-08Regeneron Pharmaceuticals, Inc.$4,541Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2022
2022-12-08Alkermes, Inc.$1,064Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2022
2022-12-07Gilead Sciences, Inc.$3,339Research paymentCash or cash equivalentPhase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-P2022
2022-12-07Gilead Sciences, Inc.$1,000Research paymentCash or cash equivalentPhase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-P2022
2022-12-07Gilead Sciences, Inc.$693Research paymentCash or cash equivalentPhase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-P2022
2022-12-05Incyte Corporation$361Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2022
2022-12-05Genentech, Inc.$295Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2022
2022-12-03Merck Sharp & Dohme LLC$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentKEYTRUDA Biological, ONCOLOGY2022
2022-12-02Merck Sharp & Dohme LLC$32,733Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792022
2022-12-01ABBVIE INC.$4,250Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYA Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allog2022
2022-12-01Janssen Research & Development, LLC$2,316Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2022
2022-12-01Janssen Research & Development, LLC$1,500Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2022
2022-12-01Janssen Research & Development, LLC$1,320Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2022
2022-12-01Janssen Research & Development, LLC$112Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2022
2022-11-28Kite Pharma, Inc.$2,685Research paymentCash or cash equivalentTecartus Drug, CELLTA Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma2022
2022-11-25Janssen Research & Development, LLC$1,500Research paymentCash or cash equivalentA Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit2022
2022-11-24ABBVIE INC.$2,000Research paymentCash or cash equivalentA Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod 2022
2022-11-24ABBVIE INC.$1,360Research paymentCash or cash equivalentA Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod 2022
2022-11-24Janssen Research & Development, LLC$904Research paymentCash or cash equivalentA Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj2022
2022-11-23Celgene Corporation$18,432Research paymentCash or cash equivalentTRANSCEND 3L+ CLL- 17004 (Ph 1/2) - An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Ch2022
2022-11-23TRILLIUM THERAPEUTICS USA, LLC$5,000Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2022
2022-11-23Daiichi Sankyo Inc.$2,714Research paymentCash or cash equivalentENHERTU Drug, ONCOLOGYDS-8201-A-U2042022
2022-11-23Regeneron Pharmaceuticals, Inc.$2,316Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2022
2022-11-23Daiichi Sankyo Inc.$2,316Research paymentCash or cash equivalentENHERTU Drug, ONCOLOGYDS-8201-A-U2042022
2022-11-23Alkermes, Inc.$1,993Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2022
2022-11-23TRILLIUM THERAPEUTICS USA, LLC$1,674Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2022
2022-11-23Regeneron Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2022
2022-11-23Regeneron Pharmaceuticals, Inc.$1,320Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2022
2022-11-23Daiichi Sankyo Inc.$1,320Research paymentCash or cash equivalentENHERTU Drug, ONCOLOGYDS-8201-A-U2042022
2022-11-23EMD Serono, Inc.$476Research paymentCash or cash equivalentA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera2022
2022-11-23Regeneron Pharmaceuticals, Inc.$442Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYPHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN2022
2022-11-23Alkermes, Inc.$250Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2022
2022-11-23Takeda Pharmaceuticals U.S.A., Inc.$215Research paymentCash or cash equivalentICLUSIG Drug, ONCOLOGYA RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T2022
2022-11-23Regeneron Pharmaceuticals, Inc.$115Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYPHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN2022
2022-11-23Alkermes, Inc.$46Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2022
2022-11-22Takeda Pharmaceuticals U.S.A., Inc.$2,946Research paymentCash or cash equivalentA RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO2022
2022-11-22Janssen Research & Development, LLC$347Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-11-22Janssen Research & Development, LLC$136Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-11-21Merck Sharp & Dohme LLC$35,500Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase 1 Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol Paclitaxel HM30181A in 2022
2022-11-21E.R. Squibb & Sons, L.L.C.$4,476Research paymentCash or cash equivalentPh I/II mono (lag3) vs combo (lag3 + nivo) (solid tumors)2022
2022-11-18National Marrow Donor Program$5,500Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (AAT) Combined with C2022
2022-11-18National Marrow Donor Program$2,304Research paymentCash or cash equivalentA Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administ2022
2022-11-18Pharmacyclics LLC, an AbbVie Company$1,000Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYStudy of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)2022
2022-11-18Pharmacyclics LLC, an AbbVie Company$831Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYStudy of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)2022
2022-11-18Pharmacyclics LLC, an AbbVie Company$80Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYStudy of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)2022
2022-11-17Daiichi Sankyo Inc.$6,175Research paymentCash or cash equivalentENHERTU Drug, ONCOLOGYDS-8201-A-U2042022
2022-11-17Regeneron Pharmaceuticals, Inc.$4,541Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2022
2022-11-17Janssen Research & Development, LLC$2,926Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-11-17Genentech, Inc.$633Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPOLARIX2022
2022-11-17Bayer Healthcare Pharmaceuticals Inc.$418Research paymentCash or cash equivalentXofigo Drug, OncologyLong Term follow up with Xofigo2022
2022-11-17Janssen Research & Development, LLC$72Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-11-17Alkermes, Inc.$13Research paymentIn-kind items and servicesA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2022
2022-11-16Janssen Research & Development, LLC$4,333Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-11-16BeiGene, Ltd.$2,000Research paymentCash or cash equivalentA Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Ho2022
2022-11-16BeiGene, Ltd.$1,360Research paymentCash or cash equivalentA Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Ho2022
2022-11-16Genentech, Inc.$325Research paymentCash or cash equivalent DrugPHASE III IPATASERTIB PLUS ABIRATERONE IN MCRPC 1ST LINE2022
2022-11-16BeiGene, Ltd.$200Research paymentCash or cash equivalentA Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Ho2022
2022-11-16Exelixis Inc.$198Research paymentCash or cash equivalentCabometyx Drug, OncologyA Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus2022
2022-11-15Takeda Pharmaceuticals U.S.A., Inc.$1,500Research paymentCash or cash equivalentICLUSIG Drug, ONCOLOGYA RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T2022
2022-11-15Takeda Pharmaceuticals U.S.A., Inc.$990Research paymentCash or cash equivalentICLUSIG Drug, ONCOLOGYA RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T2022
2022-11-15Takeda Pharmaceuticals U.S.A., Inc.$660Research paymentCash or cash equivalentICLUSIG Drug, ONCOLOGYA RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T2022
2022-11-15Genentech, Inc.$90Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2022
2022-11-14CSL Behring$2,160Research paymentIn-kind items and servicesZemaira Biological, Pulmonary/Respiratory DiseasesA Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With 2022
2022-11-11Exelixis Inc.$3,069Research paymentCash or cash equivalentCabometyx Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2022
2022-11-11Exelixis Inc.$2,038Research paymentCash or cash equivalentCabometyx Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2022
2022-11-11Exelixis Inc.$2,038Research paymentCash or cash equivalentCabometyx Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2022
2022-11-11Exelixis Inc.$660Research paymentCash or cash equivalentCabometyx Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2022
2022-11-10TRILLIUM THERAPEUTICS USA, LLC$1,990Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2022
2022-11-09Regeneron Pharmaceuticals, Inc.$14,000Research paymentCash or cash equivalentA Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo2022
2022-11-09Merck Sharp & Dohme LLC$6,060Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R2022
2022-11-09SEAGEN INC.$5,000Research paymentCash or cash equivalentA Phase 1 Study of SEA-CD70 in Myeloid Malignancies2022
2022-11-09Regeneron Pharmaceuticals, Inc.$4,760Research paymentCash or cash equivalentA Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo2022
2022-11-09Regeneron Pharmaceuticals, Inc.$4,000Research paymentCash or cash equivalentA Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo2022
2022-11-09Regeneron Pharmaceuticals, Inc.$2,500Research paymentCash or cash equivalentA Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo2022
2022-11-09Regeneron Pharmaceuticals, Inc.$2,040Research paymentCash or cash equivalentA Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo2022
2022-11-09Regeneron Pharmaceuticals, Inc.$2,000Research paymentCash or cash equivalentA Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo2022
2022-11-09SEAGEN INC.$2,000Research paymentCash or cash equivalentADCETRIS Biological, OncologyA Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or 2022
2022-11-09Regeneron Pharmaceuticals, Inc.$600Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYPHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN2022
2022-11-09Regeneron Pharmaceuticals, Inc.$400Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYPHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN2022
2022-11-09Regeneron Pharmaceuticals, Inc.$400Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYPHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN2022
2022-11-09Genentech, Inc.$200Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2022
2022-11-08Genentech, Inc.$14,000Research paymentCash or cash equivalent DrugSINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC2022
2022-11-08Genentech, Inc.$4,760Research paymentCash or cash equivalent DrugSINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC2022
2022-11-08Regeneron Pharmaceuticals, Inc.$3,536Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2022-11-08Genentech, Inc.$2,040Research paymentCash or cash equivalent DrugSINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC2022
2022-11-08Genentech, Inc.$2,000Research paymentCash or cash equivalent DrugSINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC2022
2022-11-08Genentech, Inc.$2,000Research paymentCash or cash equivalent DrugSINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC2022
2022-11-08Bayer Healthcare Pharmaceuticals Inc.$1,500Research paymentCash or cash equivalentXofigo Drug, OncologyLong Term follow up with Xofigo2022
2022-11-08Regeneron Pharmaceuticals, Inc.$367Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2022-11-08Regeneron Pharmaceuticals, Inc.$117Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022

The latest 200 records of 1,135.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyDetroit city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Detroit, MI
County
Wayne County, MI
State
Michigan
Population B01003638,5301,772,25910,077,761
Population, 2020 census P1639,1111,793,56110,077,331
Median age B0100235.237.940.2
Under 18 B0100124.8%23.6%21.2%
65 and over B0100115.1%16.6%18.6%
Households B11001257,998700,5914,076,369
Foreign born B050026.6%10.3%7.2%
Median household income B19013$39,938$60,539$72,875
Median family income B19113$49,398$79,522$93,357
Per capita income B19301$24,594$34,906$40,735
Poverty rate B1700132.7%20.8%13.2%
Unemployment rate B2302514.0%8.7%5.7%
Civilian labor force B23025268,955828,8385,018,449
Mean commute (minutes) B0801324.824.724.2
Bachelor's degree or higher B1500318.1%27.6%32.4%
Housing units B25001329,393801,0834,622,236
Owner-occupied B2500350.3%64.8%73.2%
Renters B2500349.7%35.2%26.8%
Median home value B25077$83,900$178,500$231,600
Median gross rent B25064$1,074$1,132$1,129
White, not Hispanic B0300210.8%47.9%72.4%
Black B0300275.0%36.6%13.1%
Hispanic or Latino B030028.3%6.9%5.9%
Asian B030021.7%3.7%3.4%
American Indian and Alaska Native B030020.2%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.